N6-Adenosine Methylation (m6A) RNA Modification: an Emerging Role in Cardiovascular Diseases.
Ye-Shi ChenXin-Ping OuyangXiao-Hua YuPetr NovákLe ZhouPing-Ping HeKai YinPublished in: Journal of cardiovascular translational research (2021)
N6-methyladenosine (m6A) is the most abundant and prevalent epigenetic modification of mRNA in mammals. This dynamic modification is regulated by m6A methyltransferases and demethylases, which control the fate of target mRNAs through influencing splicing, translation and decay. Recent studies suggest that m6A modification plays an important role in the progress of cardiac remodeling and cardiomyocyte contractile function. However, the exact roles of m6A in cardiovascular diseases (CVDs) have not been fully explained. In this review, we summarize the current roles of the m6A methylation in the progress of CVDs, such as cardiac remodeling, heart failure, atherosclerosis (AS), and congenital heart disease. Furthermore, we seek to explore the potential risk mechanisms of m6A in CVDs, including obesity, inflammation, adipogenesis, insulin resistance (IR), hypertension, and type 2 diabetes mellitus (T2DM), which may provide novel therapeutic targets for the treatment of CVDs.
Keyphrases
- cardiovascular disease
- insulin resistance
- congenital heart disease
- heart failure
- dna methylation
- left ventricular
- high fat diet induced
- metabolic syndrome
- type diabetes
- skeletal muscle
- genome wide
- blood pressure
- oxidative stress
- adipose tissue
- gene expression
- weight gain
- density functional theory
- endothelial cells
- cardiac resynchronization therapy
- protein kinase
- smooth muscle
- arterial hypertension
- high glucose